Study of GABA-A Receptors in the Generation of Tics in Patients With Tourette's Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-04-24

Study Completion Date

2010-03-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate how the brain generates tics in patients with Tourette's syndrome and which areas of the brain are primarily affected. Tourette's syndrome is a neuropsychiatric disorder characterized by motor and vocal tics, and is associated with behavioral and emotional disturbances, including symptoms of attention deficit hyperactivity disorder and obsessive-compulsive disorder. This study will examine whether tic generation is related to changes in brain cell receptors for a chemical messenger called gamma-aminobutyric acid (GABA).

Healthy normal volunteers and patients with Tourette's syndrome between 21 and 65 years of age may be eligible for this study. Candidates will be screened with a medical history and physical and neurological examinations.

Participants will undergo positron emission tomography (PET) scanning to measure brain blood flow. For this procedure, the subject receives an injection of H215O, a radioactive substance similar to water. A special camera detects the radiation emitted by the H215O, allowing measurement of the blood flow. Subjects will receive up to five injections of H215O during the scanning. They will also be injected with another radioactive chemical, (11C) flumazenil, which binds to GABA receptors, to measure the density and distribution of these receptors. This will reveal which areas of the brain in patients with Tourette's syndrome have abnormal binding of flumazenil compared with the brains of healthy control subjects.

During the PET procedure, the subject lies on a table in the PET scanner. A small catheter (plastic tube) is placed in an arm vein for injecting the radioactive tracers, and a mask is placed on the face to help keep the head still during scanning. The mask has large openings for eyes, nose and mouth, so that it does not interfere with talking or breathing. The entire test takes about 3 hours.

On a separate day, participants will also undergo magnetic resonance imaging (MRI), a diagnostic test that uses a magnetic field and radio waves to produce images of the brain. For this procedure, the subject lies still on a stretcher that is moved into the scanner (a narrow cylinder containing the magnet). Earplugs are worn to muffle loud noises caused by electrical switching of radio frequency circuits used in the scanning process. The scan lasts about 45 to 60 minutes.

...

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Tics in Patients With Tourette's Syndrome and Chronic Motor Tic Disorder

NCT00033995

Tourette Syndrome Tic Disorders

COMPLETED

Brain Activation in Vocal and Motor Tics

NCT00026000

Tourette's Syndrome Chronic Motor Tic Disorder Chronic Motor Vocal Disorder

COMPLETED

Magnetic Resonance Spectroscopy to Evaluate Tourette s Syndrome

NCT00030953

Tourette Syndrome

COMPLETED

Brain Activity Associated With Tics in Patients With Tourette Syndrome

NCT00141869

Tourette Syndrome

COMPLETED

Brain Activity in People With Functional Movement Disorders

NCT00448084

Functional Movement Disorders

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine if symptoms of Tourette's syndrome are due to dysfunction of GABA-ergic neurons causing disinhibition originating in basal ganglia, and involving thalamus, frontal and prefrontal cortices and contributing to tic generation.

The major inhibitory neurotransmitter in central nervous system is gamma-aminobutyric acid (GABA), which acts mainly through the GABA A receptors. Pathological processes involving GABA-ergic neurons cause alterations in the density of GABA A receptors of the targeted neurons. These changes can be visualized and measured with Positron Emission Tomography using as a radioactive ligand \[11C\] flumazenil. We will examine changes in the density and distribution of GABA A receptors in 17 adult patients with a DSM-IV-TR (American Psychiatric Association 2000) diagnosis of a tic disorder and 17 control subjects. This study should provide new information concerning localization and degree of dysfunction of GABA-ergic neurons in areas involved in Tourette's syndrome, which, in turn, might open new possibilities in pharmacological treatment of this disorder.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tourette Syndrome

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A. Patients will have clinically documented TS as defined by DSM-IV and evaluation of tics severity using Yale Tic Scale. This criterion will be established by the preliminary screening in the NINDS Movement Disorders Outpatient Clinic.

B. Patients (either male or female) will range in age from 18 to 65 years. Female patients of child-bearing potential will have a pregnancy test prior to each PET and MRI scan and specific interview prior to the study to ensure that pregnant patients will not participate in the study. Patients will be asked to stop for two weeks prior to the exam any medication that can influence the CNS. Fluoxetine will be stopped for four weeks. They will be asked to abstain from alcohol for one week before the study.

C. Seventeen normal controls will be included; controls will be screened in the NINDS Movement Disorders Outpatient Clinic, and will have neurological and physical examinations. Controls with chronic illnesses, taking any medication that affects the CNS will be excluded. They will be asked to abstain from alcohol for one week before the study.

Exclusion Criteria

A. Patients younger than 18 years old and older than 65 will be excluded from the study.

B. Patients with MRI findings consistent with brain tumors, strokes, trauma or AVMs will be excluded.

C. Patients with progressive neurological disorders other than TS will be excluded.

D. Patients with a history of significant medical disorders, or requiring chronic treatment with other drugs, which, cannot be stopped, will be excluded.

E. Patients with cancer will be excluded.

F. Patients incapable of giving an informed consent will be excluded.

G. Patients who are pregnant or nursing.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes